9 research outputs found
Clinical outcomes associated with coadministration of lopinavir/ritonavir-based ART and rifampicin-containing TB treatment.
<p>T-test, Chi-square, and Fisher’s tests used for comparisons, * p<0.05.</p
Kaplan-Meier survival curve for the impact of lopinavir/ritonavir dosing strategy among patients with HIV/TB coinfection on time until treatment discontinuation.
<p>Kaplan-Meier survival curve for the impact of lopinavir/ritonavir dosing strategy among patients with HIV/TB coinfection on time until treatment discontinuation.</p
Baseline characteristics of patients at initiation of lopinavir/ritonavir-based second line ART, according to treatment group.
<p>Baseline characteristics of patients at initiation of lopinavir/ritonavir-based second line ART, according to treatment group.</p
Resistance profile of Gram-positive bacteria.
<p>Resistance profile of Gram-positive bacteria.</p
General bacteria etiology among blood culture isolates.
<p>General bacteria etiology among blood culture isolates.</p
Map of Iraq showing area of Sulaymaniyah.
<p>Map of Iraq showing area of Sulaymaniyah.</p
Resistance profile for gram-negative bacteria.
<p>Resistance profile for gram-negative bacteria.</p
CD4 count outcomes at 12 and 30 months based on patient demographic and pre-HAART characteristics.
<p>CD4 count outcomes at 12 and 30 months based on patient demographic and pre-HAART characteristics.</p
CD4+ T-cell count trajectories and baseline characteristics predicting failure of CD4 cell count recovery.
<p><b>A</b>. CD4+ T-cell count trajectories for all 442 subjects over the course of 30 months. The red line reflects the median±SEM. <b>B</b>. OR and 95% confidence intervals (CI) for not achieving CD4 counts above 200 cells/mm<sup>3</sup> at 12 months (grey) and 500 cells/mm<sup>3</sup> at 30 months (black) depending on baseline characteristics. Shown are only factors with significant or close to significant effect in the multivariate model.</p